Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.80 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277199 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL25149515 | 0.86 | PTGS2 (0.86) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL4587731 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL4586525 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL28298821 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL14562098 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL5427092 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL6251637 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL5428698 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL6168295 | 0.81 | PTGS2 (0.75) | PTGS2PTGS1MT-CO2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| CN-112028851-B | Parecoxib sodium intermediate compound | 鲁南制药集团股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-112028850-B | Intermediate compound of parecoxib sodium | 鲁南制药集团股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-112028850-A | Intermediate compound of parecoxib sodium | 鲁南制药集团股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-112028851-A | Parecoxib sodium intermediate compound | 鲁南制药集团股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1653967-A2 | COMBINATION OF A COX-2 INHIBITOR AND AN ALKYLATING-TYPE ANTINEOPLASTIC AGENT FOR TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1653940-A1 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR | Pharmacia Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004093856-A2 | COMBINATION OF A COX-2 INHIBITOR AND AN ALKYLATING-TYPE ANTINEOPLASTIC AGENT FOR TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093868-A1 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |